Briefly: Pancreatic cancer occurs in about on in five Lynch syndrome families, increasing risk for the cancer substantially.
Colorectal cancer patients whose tumors don’t have EGFR on immunohistochemical testing can still benefit from Erbitux treatment.
Patients learn more and like medical consultations better when doctors sit side-by-side with them to view tests.
Gastroenterologists deployed in Iraq are using their skills to help military working dogs.
- Among families with Lynch syndrome, one in five had at least one person with pancreatic cancer. Data from 6,342 individuals in 147 families in familial cancer registries at Dana-Farber Cancer Institute in Boston and University of Michigan Comprehensive Cancer Center in Ann Arbor included 47 cases of pancreatic cancer in Lynch families, evenly spread between men and women. There was a 3.68 percent risk of having pancreatic cancer before age 70, almost nine times the risk in the general population. Fay Kastrinos, MD, MPH and her team reported their study results in the October 28, 2009 issue of the Journal of the American Medical Association.
- Some colorectal cancer patients whose tumors did not express the epidermal growth factor receptor (EGFR) when tested with immunohistochemical staining still responded to treatment with Erbitux© (cetuximab), when given as a single drug (monotherapy). Seven of 85 patients (8.2 percent) had tumors shrink. For the group, median time to cancer progression was 2.1 months with median overall survival of 10 months. About 40 percent of patients were alive one year after treatment began. Study results were similar to other clinical trials of cetuximab monotherapy restricted to patients with EGFR positive tumors.Rafal Wierzbicki and colleagues published their phase II clinical trial results in Investigational New Drugs, online October 15, 2009.
- When doctors and patients sat side by side at a semicircular table facing a computer screen during a consultation, they shared more information and patients said they were more satisfied with the visit than in a conventional office. The computer displayed the patient’s electronic medical record, test results, and Internet pages with other health information. Watch Dr. Victor Montori of the Mayo Clinic who led the randomized Space and Interaction Trial (SIT) discuss the results.
- Gastroenterologists in Iraq are using their skills — and their colonoscopes — to help military working dogs return to duty. Deployed in Iraq, the doctors removed buttons, tacks, and rocks swallowed by the dogs. They also stemmed bleeding, found fungal infections, and discovered a large cancer in one dog, who died. Leon Kundrotas, MD, FACG and Timothy Cassidy, DO presented their work with military dogs in a poster at the American College of Gastroenterology Annual Meeting in San Diego last week.